Clin2
NCT07267130Likely a fitTerminated

Safety study of TQC3302 inhaler in healthy adults

Chronic Obstructive Pulmonary Disease

Part of Lungs & breathing clinical trials.

This trial tests a new inhaled medication (TQC3302) in healthy adults to see if it is safe and how the body processes it. It is a first-in-human study for a potential treatment for lung conditions.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
33 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are between 18 and 55 years old.
  • You are in good general health with no chronic lung conditions, glaucoma, or prostate issues.
  • Your weight is at least 110 pounds (50 kg) for men or 99 pounds (45 kg) for women.
  • You have not used any tobacco or recreational drugs recently, and you can pass a drug test.
  • You are willing to use effective birth control from screening until 90 days after the last dose.
  • You have not had a vaccine within 30 days before the study or plan to get one during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07464587Not yet recruiting· Phase 3
Study of Inhaled TQC3721 for Moderate-to-Severe COPD

This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe chronic obstructive pulmonary disease (COPD). It aims to see if the drug can improve lung function and symptoms. For some participants, the trial is available to those who have not been in a previous TQC3721 study.

Bozhou, Anhui
NCT07147946Not yet recruiting· Phase 3
Inhaled study drug for moderate-to-severe COPD

This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe COPD. The goal is to see if it can help improve breathing and reduce flare-ups.

Bozhou, Anhui
NCT07633314Not yet recruiting· Phase 2
New COPD Inhaler Treatment Comparison Study

This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.

Yulin, Guangxi
NCT07528703Not yet recruiting· Phase 1
Safety Study of RC010 Inhaled Powder in Healthy Adults

This is an early-stage safety study testing a new inhaled medication called RC010 in healthy volunteers. Researchers want to understand how safe it is, how well people tolerate it, and how the body processes it.

Beijing, Beijing Municipality
NCT07583849Recruiting· Phase 3
Testing a new inhaled powder for COPD symptoms

This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.

Beijing, Beijing Municipality
NCT06829784Recruiting· Phase 3
Study of TQC2731 for severe asthma

This trial tests an investigational drug called TQC2731 for people with severe asthma that is not well controlled despite high-dose inhaled steroids. The study aims to see if this treatment can reduce asthma attacks.

Bozhou, Anhui

Hear when a new Chronic Obstructive Pulmonary Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.